Article Abstract

Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer

Authors: Vivek Verma, Joe Y. Chang

Abstract

Comprising a large proportion of patients with non-small cell lung cancer (NSCLC), metastatic disease is a major oncologic concern. Consequently, enormous ongoing efforts in both systemic and radiation therapy are specifically aimed at delaying progression and potentially increasing survival over historical treatment with palliative chemotherapy. One particular approach is the concept of stereotactic ablative radiotherapy (SABR) for oligometastatic disease, which refers to administering non-invasive local therapy to limited sites of gross disease in efforts to eradicate the most likely areas of progression and potential sources that generate de novo metastases.